Sustainability & Climate

The sale of Golf Cars, Inc. to Midwest Golf & Turf creates a new regional leader, signaling major consolidation in the booming utility vehicle market.

Award-winning executives are turning chaotic truck yards into strategic assets, tackling the food industry's biggest challenges from the ground up.

Robot orders surged 6.6% in 2025, driven by food, electronics, and life sciences, marking a major shift away from traditional automotive dominance.

A 90-year-old family propane business is acquired by a PE-backed firm, signaling a major shift in the fragmented energy distribution market.

New preclinical data suggests Arcellx's CAR T therapy may offer a safer profile than rivals, potentially avoiding severe neurological side effects.

A new survey reveals championship fleets operate like elite sports teams, prioritizing safety, real-time data, and recognizing their most valuable players.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

A new triple-batch collection honors American history, pushing the boundaries of proof and collectibility for the coveted ultra-premium whiskey brand.

As spring tick season begins, a devastating disease threatens cattle herds. Experts urge early vaccination to prevent massive economic and animal losses.

Italian Exhibition Group unveils its 2025-2030 strategy, targeting massive growth with landmark venue expansions and strategic global acquisitions.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

A new agreement with Willis Lease Finance gives Nauru Airlines crucial operational stability, securing its role as a key air bridge in the South Pacific.

A top KLAS award reveals a new era in healthcare cybersecurity, where measurable risk reduction and financial value are becoming more important than ever.

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.

Digital asset firm Streamex appoints NYU's Anthony Marciano, signaling a strategic push for institutional credibility and M&A amid financial headwinds.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

A new poll for America's 250th birthday shows a nation that reveres its Founders but has abandoned their core beliefs on rights and government.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.